BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet (original) (raw)

What are BRCA1 and BRCA2?

BRCA1 (BReast CAncer gene 1) and BRCA2 (BReast CAncer gene 2) are genes that produce proteins that help repair damaged DNA. Everyone has two copies of each of these genes—one copy inherited from each parent.

People who inherit a harmful change (also called a mutation or pathogenic variant) in one of these genes have increased risks of several cancers—most notably breast and ovarian cancer, but also several other types of cancer (1, 2). People who have inherited a harmful change in BRCA1 or BRCA2 also tend to develop cancer at younger ages than people who do not have such a variant.

Nearly everyone who inherits a harmful change in the BRCA1 or BRCA2 gene from one parent has a normal second copy of the gene inherited from the other parent. Having one normal copy of either gene is enough to protect cells from becoming cancer. But the normal copy can change or be lost during someone’s lifetime. Such a change is called a somatic alteration. A cell with a somatic alteration in the only normal copy of one of these genes doesn’t have sufficient DNA repair ability and can become cancer.

How much does an inherited harmful change in BRCA1 or BRCA2 increase the risks of breast and ovarian cancer?

The risks of developing breast and ovarian cancer are markedly increased in people who inherit a harmful change in BRCA1 or BRCA2 (1, 3–7).

• Female breast cancer: More than 60% of women who inherit a harmful change in BRCA1 or BRCA2 will develop breast cancer during their lifetime (2). By contrast, about 13% of women in the general population will develop breast cancer during their lifetime.
  Among women who have been diagnosed with breast cancer, those who have an inherited harmful change in BRCA1 or BRCA2 have an increased risk of developing cancer in the opposite (contralateral) breast in the future compared with those who do not have such a change (8). About 30%–40% of breast cancer survivors with inherited BRCA1 changes and 25% of those with inherited BRCA2 changes will develop contralateral breast cancer by 20 years after their first breast cancer diagnosis, compared with about 8% of those in the general population (2, 9).
• Male breast cancer: About 0.2%–1.2% of men with an inherited harmful change in BRCA1 and 1.8%–7.1% with an inherited harmful change in BRCA2 will develop breast cancer by age 70 (2). By contrast, about 0.1% of men in the general population will develop breast cancer by age 70. Given the rarity of breast cancer in men with harmful BRCA changes, their risk of contralateral breast cancer has not been estimated.
• Ovarian cancer: About 39%–58% of women who inherit a harmful change in BRCA1 and 13%–29% of women who inherit a harmful change in BRCA2 will develop ovarian cancer (which includes fallopian tube cancer and primary peritoneal cancer) during their lifetime (2). By contrast, about 1.1% of women in the general population will develop ovarian cancer during their lifetime.

What other cancers are linked to inherited harmful changes in BRCA1 and BRCA2?

People who inherit harmful changes in BRCA1 or BRCA2 have an increased risk of several additional cancers (1, 10–12).

• Pancreatic cancer: Up to 5% of individuals with harmful changes in BRCA1 and 5%–10% of those with harmful changes in BRCA2 will develop pancreatic cancer during their lifetime (2). By contrast, about 1.7% of people in the general population will develop pancreatic cancer during their lifetime.
• Prostate cancer: About 7%–26% of men with harmful changes in BRCA1 and 19%–61% of those with harmful changes in BRCA2 will get prostate cancer by age 80 (2). By contrast, about 10.6% of men in the general population will develop prostate cancer by age 80.
• Other cancers: Some studies have suggested that people with harmful changes in the BRCA genes have increased risks of melanoma (both skin and eye), stomach cancer, and a rare type of endometrial cancer called uterine serous carcinoma (4, 13–15). However, these associations are not yet certain.
  In addition, individuals who inherit genetic changes in both copies of their BRCA1 or BRCA2 gene develop subtypes of Fanconi anemia, a rare syndrome that is associated with solid tumors and the development of acute myeloid leukemia, often in childhood (16–18).

Individuals who inherit a harmful change in each of the BRCA genes (one in BRCA1 and one in BRCA2)—although rare—appear to have cancer risks that resemble those of individuals that inherit harmful changes in BRCA1 (19). Inheritance of harmful mutations in both BRCA1 and BRCA2 is more common in populations that have a higher prevalence of inherited BRCA mutations (e.g., Ashkenazi Jewish population).

Does the likelihood of having a BRCA gene mutation differ among populations?

Yes. The prevalence of harmful BRCA gene changes in the general population is about 0.2%–0.3% (or about 1 in 400). However, in certain populations that are geographically or culturally distinct, the prevalence of specific BRCA mutations—called founder mutations—is higher. For example, about 2% of people of Ashkenazi Jewish descent carry a harmful change in one of these two genes, with the change usually being one of three specific mutations. Other populations, such as Norwegian, Dutch, Icelandic, Hispanic, West African, African American, Sephardi Jewish, and Bahamanian people, also have founder mutations (20–28).

Different racial, ethnic, and geographic populations may carry different changes in these genes. For instance, African Americans have BRCA1 changes that are not seen in other racial or ethnic groups in the United States (29–31).

Who should consider genetic counseling and testing for inherited harmful changes in BRCA1 and BRCA2?

Anyone who is concerned that they may have inherited a harmful change in the BRCA1 or BRCA2 gene should discuss their concerns with their health care provider or a genetic counselor to see if testing for an inherited change, sometimes called germline genetic testing, may be right for them. Expert groups recommend that testing be focused on those who have a higher likelihood of carrying a harmful change in BRCA1 or BRCA2 (2, 32, 33).

Testing can be appropriate for both people without cancer and people who have been diagnosed with cancer. If someone knows they have inherited a harmful change in one of these genes, they can take steps to reduce their risk of developing cancer or to detect cancer early. If they have cancer, the information about the genetic change may be important for selecting treatment. Also, people can share the results of testing with blood relatives, who can then better understand their own cancer risk. Genetic counseling will allow for a discussion of the implications of testing for BRCA changes so that someone can give informed consent to the process.

Before having testing, people should discuss with their genetic counselor both the benefits and possible downsides of genetic testing.

A risk assessment is usually done before testing, in which a person and their genetic counselor or other health care provider review factors that make it more likely that they inherited a harmful change in BRCA1 or BRCA2. These factors include

• having a family member with an inherited harmful change in the BRCA1 or BRCA2 gene
• having Ashkenazi Jewish heritage
• having a personal or family history of breast cancer at age 50 or younger
• having a personal or family history of ovarian cancer, male breast cancer, pancreatic cancer, or metastatic or high-risk prostate cancer

Professional groups do not recommend that children under age 18 undergo genetic testing for BRCA1 and BRCA2 changes. This is because there are no risk reduction strategies that are specifically meant for children, and children are very unlikely to develop a cancer related to an inherited BRCA change.

How is genetic testing for harmful changes in BRCA1 and BRCA2 done?

Testing for inherited harmful changes in BRCA1 and BRCA2 may be done using a blood or saliva sample. That is because when a mutation is inherited, it is found in every cell in the body, including blood cells and cells that are present in saliva. Sometimes people with cancer find out that they have a harmful change in BRCA1 or BRCA2 when their tumor is tested to see if they are a candidate for treatment with a particular targeted therapy. Because harmful BRCA changes found in the tumor may have been inherited or may have arisen later in someone’s lifetime, someone with such a change in their tumor should consider getting tested to find out if the change was inherited.

If a genetic counselor or other health care professional is ordering the testing, you will generally provide a sample at the doctor’s office.

People can also have germline genetic testing on their own, through direct-to-consumer (DTC) testing or via direct access (patient-initiated) testing. Genetic counseling is recommended for people who pursue DTC testing to help them understand the test results and to make sure the most appropriate test is done. People should also be aware that because some DTC tests do not test for every harmful change in the two genes, it is possible that someone could have a harmful change in BRCA1 or BRCA2 that the DTC test doesn’t detect.

Does health insurance cover the cost of genetic testing for changes in BRCA1 and BRCA2?

People considering testing for inherited harmful changes in BRCA1 and BRCA2 may want to confirm their insurance coverage for genetic counseling and testing. Genetic counselors can often help answer questions about insurance coverage for genetic testing.

Some genetic testing companies may offer testing for inherited changes in BRCA1 and BRCA2 at no charge to patients who lack insurance and meet specific financial and medical criteria.

What do BRCA1 and BRCA2 genetic test results mean?

Testing for inherited changes in BRCA1 and BRCA2 can give several possible results: a positive result (a harmful change in the gene is present), a negative result (no harmful gene change is present), or a gene change (variant) of uncertain significance (VUS) result.

Positive result. A positive test result indicates that a person has a harmful change in BRCA1 or BRCA2 (these are typically called “pathogenic” or “likely pathogenic” variants on laboratory test reports) and has an increased risk of developing certain cancers. However, a positive test result cannot tell whether or when the tested individual will develop cancer. Some people who inherit a harmful change in BRCA1 or BRCA2 never develop cancer.

Negative result. A negative test result can have several meanings, depending on the personal and family medical history of the person who is tested and whether a harmful genetic change has already been identified in the family.

• If a close blood relative of the tested person is known to carry a harmful change in BRCA1 or BRCA2 and the laboratory was aware of that variant when performing the testing, a negative test result is clear: it means the tested person did not inherit the harmful change that is present in the family and cannot pass it to their children. A negative test result does not mean that a person will not get cancer They still have the same cancer risks as those in the general population and, depending on their family history, may still be at elevated risk for cancer.
• If the tested person has no personal history of cancer or their family isn’t known to carry a harmful variant, then the negative result does not provide additional information about their risk of cancer beyond what is known about their family history and other risk factors they may have.

Variant of uncertain significance (VUS) result. Sometimes, a genetic test finds a change in BRCA1 or BRCA2 for which there is not enough data available to conclude that it increases cancer risk. This type of test result is called “a variant of uncertain significance,” or VUS. Most often, as more data become available VUS are reclassified as being benign (do not increase cancer risk). Until a VUS is reclassified, whether as harmful or benign, management of cancer risk should be based on family history and other risk factors. Genetic counseling can help a person understand what any of these results may mean for the tested person and their blood relatives, including future generations.

How can a person who has inherited a harmful change in BRCA1 or BRCA2 manage their risk of cancer?

Individuals who have inherited a harmful change in BRCA1 or BRCA2 have several options for reducing cancer risk. These include enhanced screening, risk-reducing surgery (sometimes referred to as prophylactic or preventive surgery), and taking medication to reduce their risk.

Enhanced screening. Professional groups generally recommend that women who have inherited harmful changes in BRCA1 and BRCA2 start breast cancer screening at younger ages and have screening with magnetic resonance imaging (MRI; with or without contrast) in addition to mammography.

No effective ovarian cancer screening methods are known. In the past, some doctors recommended transvaginal ultrasound and blood tests for the CA-125 antigen (which can be present at higher-than-normal levels in women with ovarian cancer) for ovarian cancer screening in women with harmful changes in BRCA1 or BRCA2. However, neither method appears to detect ovarian tumors early enough to improve long-term survival (34).

Men with harmful inherited changes in a BRCA gene should discuss screening options with their health care provider. Some guidelines recommend that men who carry harmful changes in BRCA1 or BRCA2 undergo screening for breast and prostate cancers (2). This includes an annual mammogram and prostate cancer screening, particularly for men with harmful changes in BRCA2, and possible prostate screening for men with harmful changes in BRCA1.

Some organizations recommend the use of ultrasound or MRI/magnetic retrograde cholangiopancreatography to screen for pancreatic cancer in people who are known to have inherited a harmful change in BRCA1 or BRCA2 and who have a close blood relative with pancreatic cancer (2, 35–37). Studies are ongoing to investigate whether screening people at increased risk for pancreatic cancer reduces their risk of dying from the disease.

These screening approaches all have potential harms as well as possible benefits. For example, MRI is more likely than mammography to result in false-positive findings.

Risk-reducing surgery. Risk-reducing, or prophylactic, surgery involves removing as much of the “at-risk” tissue—that is, the tissue where cancer may develop—as possible. Women may choose to have both breasts removed (bilateral risk-reducing mastectomy) to reduce their risk of breast cancer. Surgery to remove the ovaries and fallopian tubes (bilateral risk-reducing salpingo-oophorectomy) can help reduce the risk of ovarian cancer and, possibly, breast cancer. (Ovarian cancers often originate in the fallopian tubes, so they are removed along with the ovaries.) Salpingectomy—the removal of the fallopian tubes only with preservation of the ovaries until after menopause—has been found to reduce the risk of ovarian cancer in the general population and is being studied as an option for premenopausal women with harmful changes in BRCA1 or BRCA2 who are not yet ready for a full salpingo-ophorectomy (38).

Such surgeries are irreversible, and each has potential complications or harms. These include bleeding or infection, concerns about body image (bilateral risk-reducing mastectomy), and early menopause in premenopausal women (bilateral risk-reducing salpingo-oophorectomy).

Risk-reducing surgery does not guarantee that cancer will not develop because these procedures cannot remove all of the tissue that may become cancerous.

Risk-reducing medications (sometimes called chemoprevention). Tamoxifen and raloxifene are approved by the Food and Drug Administration to reduce breast cancer risk in women who, based on their personal and family medical history, have an elevated risk of breast cancer. It is not yet clear whether these medications can be used to prevent breast cancer in women with greatly increased risk due to inherited harmful mutations in BRCA1, BRCA2, or other genes (39). However, tamoxifen may lower the risk of contralateral breast cancer among BRCA1 and BRCA2 variant carriers previously diagnosed with breast cancer (40). And there is evidence that tamoxifen reduces the risk of estrogen receptor–positive breast cancer among BRCA2 mutation carriers (41).

Even though these medications are not indicated for women with BRCA gene mutations, they may be an option for women who cannot or choose not to undergo risk-reducing surgery.

Oral contraceptives are another potential option to reduce the risk of ovarian cancer. Both women in the general population, as well as those with harmful BRCA1 or BRCA2 variants, who have ever used oral contraceptives (birth control pills) have about a 50% lower risk of ovarian cancer than women who have never used oral contraceptives (42). Potential harms of oral contraceptives include an increased risk of breast cancer, an increased risk that a human papillomavirus (HPV) infection will become cervical cancer, and possible cardiovascular effects among older reproductive-age women.

Another form of birth control, the levonorgestrel intrauterine device, has been associated with a reduced risk of ovarian cancer in people at average risk of the disease (43–45). Whether this device reduces ovarian cancer risk in people with harmful changes in BRCA1 or BRCA2 is not yet known.

Do inherited BRCA changes affect cancer treatment?

Anticancer agents that act by damaging DNA, such as cisplatin, can be effective treatments for tumors that develop in people who have inherited harmful changes in BRCA1 or BRCA2 because the mutated genes cause defective DNA repair (46). Cancer cells that cannot repair DNA damaged by cisplatin or similar chemotherapy drugs are more likely to be killed by these drugs.

Cancer cells that have harmful changes in BRCA1 or _BRCA2_—whether the changes are inherited or occur during life—can also be treated effectively with drugs called PARP inhibitors, which block the repair of DNA damage. Four PARP inhibitors—olaparib (Lynparza), rucaparib (Rubraca), niraparib (Zejula), and talazoparib (Talzenna)—are approved by the FDA to treat certain cancers bearing harmful changes in BRCA1 or BRCA2.

Breast cancers in people with inherited harmful changes in BRCA1 are more likely than breast cancers that develop in people without these gene changes or people in the general population to be triple negative (that is, to lack estrogen receptors and progesterone receptors and to have little or no HER2/neu protein). Because triple-negative breast cancers lack these treatment targets, they are harder to treat and have a poorer prognosis than other types of breast cancer.

If someone has tumor genetic testing that reveals the presence of a harmful change in BRCA1 or BRCA2 in the tumor, they should discuss with their health care provider whether to consider having a germline genetic test to determine if the change was inherited or if it occurred during development of the tumor. Knowing if the change was inherited is important for that individual to understand their risks to potentially develop other cancers in the future. It can also provide an opportunity for family members to learn about their own cancer risks.

Selected References

1. Petrucelli N, Daly MB, Pal T. _BRCA1_- and _BRCA2_-associated hereditary breast and ovarian cancer. 1998 Sep 4 [Updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1247/
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024. Available online with free registration. Last accessed July 16, 2024.
3. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 2007; 25(11):1329–1333.
   [PubMed Abstract]
4. Li S, Silvestri V, Leslie G, et al. Cancer risks associated With BRCA1 and BRCA2 pathogenic variants. Journal of Clinical Oncology 2022; 40(14):1529–1541.
   [PubMed Abstract]
5. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute 2007; 99(23):1811–1814.
   [PubMed Abstract]
6. Evans DG, Susnerwala I, Dawson J, et al. Risk of breast cancer in male BRCA2 carriers. Journal of Medical Genetics 2010; 47(10):710–711.
   [PubMed Abstract]
7. Chen J, Bae E, Zhang L, et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-oophorectomy: An updated meta-analysis. JNCI Cancer Spectrum 2020; 4(4):pkaa029.
   [PubMed Abstract]
8. Yadav S, Boddicker NJ, Na J, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Journal of Clinical Oncology 2023; 41(9):1703–1713.
   [PubMed Abstract]
9. Giannakeas V, Lim DW, Narod SA. The risk of contralateral breast cancer: A SEER-based analysis. British Journal of Cancer 2021; 125(4):601–610.
   [PubMed Abstract]
10. Pilarski R. The role of BRCA testing in hereditary pancreatic and prostate cancer families. American Society of Clinical Oncology educational book / ASCO 2019; 39:79–86.
    [PubMed Abstract]
11. Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. Journal of Clinical Oncology 2017; 35(20):2240–2250.
    [PubMed Abstract]
12. Nyberg T, Frost D, Barrowdale D, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: A prospective cohort study. European Urology 2020; 77(1):24–35.
    [PubMed Abstract]
13. Gumaste PV, Penn LA, Cymerman RM, et al. Skin cancer risk in BRCA1/2 mutation carriers. British Journal of Dermatology 2015; 172(6):1498–1506.
    [PubMed Abstract]
14. de Jonge MM, de Kroon CD, Jenner DJ, et al. Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: Multicenter cohort study. Journal of the National Cancer Institute 2021; 113(9):1203–1211.
    [PubMed Abstract]
15. Sherman ME, Foulkes WD. BRCA1/2 and endometrial cancer risk: Implications for management. Journal of the National Cancer Institute 2021; 113 (9): djab037. Published online March 12, 2021.
16. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297(5581):606–609.
    [PubMed Abstract]
17. Alter BP. Fanconi anemia and the development of leukemia. Best Practice & Research Clinical Haematology 2014; 27(3–4):214–221.
    [PubMed Abstract]
18. Sawyer SL, Tian L, Kähkönen M, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discovery 2015; 5(2):135–142.
    [PubMed Abstract]
19. Rebbeck TR, Friebel TM, Mitra N, et al. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research 2016; 18(1):112.
    [PubMed Abstract]
20. Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019; 322(7):666–685.
    [PubMed Abstract]
21. Weitzel JN, Lagos V, Blazer KR, et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiology, Biomarkers & Prevention 2005; 14(7):1666–1671.
    [PubMed Abstract]
22. Weitzel JN, Lagos VI, Herzog JS, et al. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiology, Biomarkers & Prevention 2007; 16(8):1615–1620.
    [PubMed Abstract]
23. Mefford HC, Baumbach L, Panguluri RC, et al. Evidence for a BRCA1 founder mutation in families of West African ancestry. American Journal of Human Genetics 1999; 65(2):575–578. doi: 10.1086/302511
24. Tonin PN, Mes-Masson AM, Futreal PA, et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. American Journal of Human Genetics 1998; 63(5):1341–1351.
    [PubMed Abstract]
25. Gal I, Gershoni Baruch R, et al. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: Occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. Familial Cancer 2004; 3(1):11–14.
    [PubMed Abstract]
26. Szwiec M, Jakubowska A, Górski B, et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: An update. Clinical Genetics 2015; 87(3):288–292.
    [PubMed Abstract]
27. Sagi M, Eilat A, Ben Avi L, et al. Two BRCA1/2 founder mutations in Jews of Sephardic origin. Familial Cancer 2011; 10(1):59–63.
    [PubMed Abstract]
28. Donenberg T, Lunn J, Curling D, et al. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Research and Treatment 2011; 125(2):591–596.
    [PubMed Abstract]
29. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 2009; 115(10):2222–2233.
    [PubMed Abstract]
30. Kurian AW. BRCA1 and BRCA2 mutations across race and ethnicity: Distribution and clinical implications. Current Opinion in Obstetrics & Gynecology 2010; 22(1):72–78.
    [PubMed Abstract]
31. Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Human Mutation 2018; 39(5):593–620.
    [PubMed Abstract]
32. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2019; 322(7):652–665.
    [PubMed Abstract]
33. Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. Journal of Clinical Oncology 2020; 38(11):1222–1245.
    [PubMed Abstract]
34. Evans DG, Gaarenstroom KN, Stirling D, et al. Screening for familial ovarian cancer: Poor survival of BRCA1/2 related cancers. Journal of Medical Genetics 2009; 46(9):593–597.
    [PubMed Abstract]
35. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69(1):7–17.
    [PubMed Abstract]
36. Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: Expert review. Gastroenterology 2020; 159(1):358–362.
    [PubMed Abstract]
37. Sawhney MS, Calderwood AH, Thosani NC, et al; Prepared by: ASGE Standards of Practice Committee. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: Summary and recommendations. Gastrointestinal Endoscopy 2022; 95(5):817–826. doi: 10.1016/j.gie.2021.12.001
38. Gaba F, Goyal S, Marks D, et al. Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: A qualitative study. Journal of Medical Genetics 2022; 59(2):122–132.
    [PubMed Abstract]
39. Singer CF. Nonsurgical prevention strategies in BRCA1 and BRCA2 mutation carriers. Breast Care (Basel) 2021; 16(2):144–148.
    [PubMed Abstract]
40. Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology 2013; 31(25):3091–3099.
    [PubMed Abstract]
41. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286(18):2251–2556.
    [PubMed Abstract]
42. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case–control study. Lancet Oncology 2007; 8(1):26–34.
    [PubMed Abstract]
43. Wheeler LJ, Desanto K, Teal SB, Sheeder J, Guntupalli SR. Intrauterine device use and ovarian cancer risk: A systematic review and meta-analysis. Obstetrics and Gynecology 2019; 134(4):791–800.
    [PubMed Abstract]
44. Balayla J, Gil Y, Lasry A, Mitric C. Ever-use of the intra-uterine device and the risk of ovarian cancer. Journal of Obstetrics and Gynaecology 2021; 41(6):848–853.
    [PubMed Abstract]
45. Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: An expert review. American Journal of Obstetrics and Gynecology 2023; 229(2):93–100.
    [PubMed Abstract]
46. Tung NM, Garber JE. BRCA1/2 testing: Therapeutic implications for breast cancer management. British Journal of Cancer 2018; 119(2):141–152.
    [PubMed Abstract]

• Reviewed: July 19, 2024

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “BRCA Gene Changes: Cancer Risk and Genetic Testing was originally published by the National Cancer Institute.”